Trial Profile
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Amgen
- 14 Feb 2017 Results published in the British Journal of Dermatology
- 18 May 2016 Status changed from completed to discontinued because of business decision due to slow enrollment.
- 24 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.